Price
$19.85
Increased by +0.10%
Dollar Volume
23.47 M
ADR%
3.48
Earnings Report Date (estimate)
Feb 27, 23 (-0.24)
Market Cap.
3.21 B
Shares Float
119.61 M
Shares Outstanding
161.93 M
Beta
0.59
Price / Earnings
-14.88
BPR
215.46
20D Range
16.70 20.11
50D Range
14.45 20.11
200D Range
12.24 22.70
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 2, 22 -0.17
Decreased by -88.89%
-0.19
Increased by +10.53%
Aug 8, 22 -0.21
Increased by +22.22%
-0.25
Increased by +16.00%
May 4, 22 -0.70
Decreased by -66.67%
-0.60
Decreased by -16.67%
Feb 28, 22 -0.27
Increased by +35.71%
-0.24
Decreased by -12.50%
Nov 8, 21 -0.09
Increased by +83.33%
-0.26
Increased by +65.38%
Aug 4, 21 -0.27
Increased by 0.00%
-0.30
Increased by +10.00%
May 5, 21 -0.42
Increased by +26.32%
-0.53
Increased by +20.75%
Feb 24, 21 -0.42
Decreased by -23.53%
-0.47
Increased by +10.64%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 130.71 M
Decreased by -0.68%
-27.18 M
Decreased by -88.03%
Decreased by -20.80%
Decreased by -89.32%
Jun 30, 22 134.56 M
Increased by +16.79%
-34.01 M
Increased by +22.47%
Decreased by -25.28%
Increased by +33.62%
Mar 31, 22 115.47 M
Increased by +8.37%
-113.06 M
Decreased by -70.14%
Decreased by -97.91%
Decreased by -57.01%
Dec 31, 21 130.76 M
Increased by +8.06%
-43.09 M
Increased by +35.45%
Decreased by -32.96%
Increased by +40.26%
Sep 30, 21 131.61 M
Increased by +9.15%
-14.46 M
Increased by +82.92%
Decreased by -10.98%
Increased by +84.36%
Jun 30, 21 115.22 M
Increased by +4.65%
-43.87 M
Decreased by -4.11%
Decreased by -38.08%
Increased by +0.52%
Mar 31, 21 106.55 M
Increased by +18.30%
-66.45 M
Increased by +24.51%
Decreased by -62.36%
Increased by +36.19%
Dec 31, 20 121.01 M
Increased by +23.07%
-66.76 M
Decreased by -25.88%
Decreased by -55.17%
Decreased by -2.28%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.